n-3 Fatty acids and their role in nephrologic practice.
During the past year, a newly reported clinical trial has strengthened the argument for recommending daily treatment with n-3 polyunsaturated fatty acids in patients with immunoglobulin A nephropathy (the most common form of primary glomerulonephritis in the world) who are at high risk for progression of renal disease. Studies are underway that involve a combination of cyclosporine A, a commonly prescribed immunosuppressive agent in solid-organ transplantation, with a high-potency n-3 polyunsaturated fatty acid to reduce cyclosporine toxicity. Two studies reported during the past year show promise that dietary supplementation with n-3 polyunsaturated fatty acids will substantially decrease vascular access graft thrombosis in patients receiving maintenance hemodialysis, and may reduce hypercalciuria in patients who suffer from kidney stones.
Donadio
J V
JV
Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA. donadio.james@mayo.edu
D002408:Catheters, Indwelling / Q000009:adverse effects; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005922:Glomerulonephritis, IGA / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D009398:Nephrology / Q000379:methods*; D011364:Professional Practice; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control
D015525:Fatty Acids, Omega-3; D007166:Immunosuppressive Agents; D016572:Cyclosporine